MATTIA, ELENA
 Distribuzione geografica
Continente #
NA - Nord America 1.010
EU - Europa 441
AS - Asia 74
Totale 1.525
Nazione #
US - Stati Uniti d'America 1.010
IT - Italia 330
CN - Cina 51
DE - Germania 35
FI - Finlandia 21
SG - Singapore 15
GB - Regno Unito 12
FR - Francia 10
SE - Svezia 9
CH - Svizzera 6
VN - Vietnam 6
UA - Ucraina 5
NL - Olanda 4
CZ - Repubblica Ceca 3
BE - Belgio 2
IE - Irlanda 2
CY - Cipro 1
IR - Iran 1
PL - Polonia 1
RO - Romania 1
Totale 1.525
Città #
Fairfield 177
Chandler 124
Ann Arbor 98
Ashburn 90
Houston 90
Woodbridge 71
Seattle 57
Wilmington 50
Cambridge 44
Milan 36
Rome 29
Des Moines 18
Medford 15
Princeton 15
Helsinki 14
Naples 14
Florence 13
Roxbury 13
Jacksonville 12
Padova 12
San Diego 12
Turin 10
Singapore 9
Beijing 8
Boardman 8
Dearborn 8
Nanjing 8
Cagliari 7
New York 7
Bologna 6
Jinan 6
Genoa 5
Modena 5
Bari 4
Lucca 4
Parma 4
Zurich 4
Alessandria 3
Bergamo 3
Brno 3
Favaro Veneto 3
Giugliano in Campania 3
Hebei 3
Lissone 3
London 3
Salerno 3
Trieste 3
Amsterdam 2
Ancona 2
Avellino 2
Bassano del Grappa 2
Bonate Sotto 2
Brescia 2
Brussels 2
Bussero 2
Campobasso 2
Carrodano 2
Cinisello Balsamo 2
Collegno 2
Corsico 2
Desio 2
Empoli 2
Fiume Veneto 2
Gardonne 2
Giussano 2
Guangzhou 2
Hangzhou 2
Hanover 2
Kilburn 2
Kunming 2
Legnano 2
Livorno 2
Monserrato 2
Montano Lucino 2
Novara 2
Nürnberg 2
Palermo 2
Pavia 2
Perugia 2
Pescara 2
Pisa 2
Prato 2
Radda in Chianti 2
Rocca San Felice 2
Sacile 2
San Costanzo 2
Shanghai 2
Shenyang 2
Teramo 2
Terrassa Padovana 2
Treviso 2
Verona 2
Villongo 2
Washington 2
Albignasego 1
Andover 1
Ascoli Piceno 1
Asti 1
Auburn Hills 1
Ballykisteen 1
Totale 1.237
Nome #
Contributo alla determinazione degli anticorpi anticardiolipina e anti - beta2 glicoproteina I 406
Erosive osteoarthritis, psoriatic arthritis and pseudogout; a casual association? 159
Catastrophic antiphospholipid syndrome: Lessons from 14 cases successfully treated in a single center. A narrative report 107
Clinical and laboratory characteristics of isolated lupus anticoagulants 101
Relationship between antiphosphatidylserine/prothrombin and conventional antiphospholipid antibodies in primary antiphospholipid syndrome. 96
The clinical performance of a chemiluminescent immunoassay in detecting anti-cardiolipin and anti-β2 glycoprotein i antibodies. A comparison with a homemade ELISA method 96
IgA anticardiolipin and IgA anti-β2 glycoprotein I antibody positivity determined by fluorescence enzyme immunoassay in primary antiphospholipid syndrome. 90
Circulating microparticles in pregnant patients with primary anti-phospholipid syndrome: an exploratory study 87
Low titer, isolated anti Ro/SSA 60 kd antibodies is correlated with positive pregnancy outcomes in women at risk of congenital heart block 83
Maternal autoantibody profiles at risk for autoimmune congenital heart block: a prospective study in high-risk patients 70
Antiphosphatidylserine/prothrombin antibodies as biomarkers to identify severe primary antiphospholipid syndrome 64
Clinical value of anti-domain I-β2Glycoprotein 1 antibodies in antiphospholipid antibody carriers. A single centre, prospective observational follow-up study 60
Detection of autoantibodies to the p200-epitope of SSA/Ro52 antigen. A comparison of two laboratory assays 54
IgG phosphatidylserine/prothrombin antibodies as a risk factor of thrombosis in antiphospholipid antibody carriers. 48
Fluorinated steroids are not superior to any treatment to ameliorate the outcome of autoimmune mediated congenital heart block: a systematic review of the literature and meta-analysis 26
Totale 1.547
Categoria #
all - tutte 4.943
article - articoli 4.095
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.038


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020268 29 13 5 22 31 21 36 31 35 16 13 16
2020/2021159 10 24 6 13 1 6 5 22 21 14 29 8
2021/2022231 9 26 21 12 7 15 11 20 18 20 21 51
2022/2023327 51 38 18 37 43 35 17 22 29 6 16 15
2023/2024320 13 16 43 28 29 32 24 21 16 30 25 43
2024/20259 9 0 0 0 0 0 0 0 0 0 0 0
Totale 1.547